No Data
Shaky Earnings May Not Tell The Whole Story For SMO ClinPlusLTD (SZSE:301257)
Prius: Third quarter report 2024
Puresis (301257.SZ) released its performance for the first three quarters, with a net income of 72.2643 million yuan, a decrease of 28.39%.
Puresis (301257.SZ) released the third quarter report of 2024. The company's revenue for the first three quarters was 5....
Pruess (301257.SZ) net income in the first three quarters was 72.2643 million yuan, a decrease of 28.39% year-on-year.
Grace Times reported on October 29th that Prose (301257.SZ) released the third quarter report of 2024, with the company achieving revenue of 0.594 billion yuan in the first three quarters, a year-on-year increase of 9.17%; net income of 72.2643 million yuan, a year-on-year decrease of 28.39%. Among them, the third quarter achieved revenue of 0.199 billion yuan, a year-on-year increase of 2.03%; net income of 17.3413 million yuan, a year-on-year decrease of 55.50%.
Puresci (301257.SZ): Shareholders Zhaotai and Huiqiao Hongjia plan to collectively reduce their shareholding by no more than 2.7%.
On October 15, GeLongHui announced that shareholder Guan Zhaotai plans to reduce the company's shares by no more than 1,590,100 shares (1.9999% of the total share capital of the company) through centralized bidding and/or block trading within 3 months after 15 trading days from the date of this announcement. Huiqiao Hongjia plans to reduce the company's shares by no more than 557,300 shares (0.7009% of the total share capital of the company) within 3 months after 3 trading days from the date of this announcement through block trading and/or centralized bidding trading.
Should You Buy SMO ClinPlus CO.,LTD. (SZSE:301257) For Its Upcoming Dividend?
Is SMO ClinPlus CO.,LTD.'s (SZSE:301257) Recent Stock Performance Tethered To Its Strong Fundamentals?No Data
No Data
